Published in World J Gastroenterol on February 07, 2010
High Flow-Mediated Vasodilatation Predicts Pulmonary Edema in Liver Transplant Patients. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.79
Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart (2002) 1.89
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Evidence of vagal neuropathy in chronic alcoholics. Lancet (1980) 1.62
Autonomic and peripheral neuropathy in primary biliary cirrhosis. J Hepatol (1993) 1.62
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology (1994) 1.56
Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology (1996) 1.47
Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut (2008) 1.45
Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation (1996) 1.31
Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis (1987) 1.17
Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl (2000) 1.13
Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology (1993) 1.12
Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl (2004) 1.07
Role of vagal neuropathy in the hyponatraemia of alcoholic cirrhosis. Br Med J (Clin Res Ed) (1986) 1.01
Cardiovascular complications following liver transplantation. Clin Transplant (1995) 1.01
The sympathetic nervous system in liver disease. J Hepatol (1998) 1.01
Decreased vascular responsiveness to noradrenaline following regular ethanol consumption. Br J Clin Pharmacol (1985) 1.00
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Systemic hemodynamic and cardiac function changes in patients undergoing orthotopic liver transplantation. Chest (1990) 0.91
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Vagal neuropathy in chronic alcoholics: relation to ethanol consumption. Alcohol Alcohol (1989) 0.90
Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med (1995) 0.89
Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. Am Rev Respir Dis (1989) 0.89
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
High cardiac output of advanced liver disease persists after orthotopic liver transplantation. Hepatology (1992) 0.87
Arteriovenous shunting, hemodynamic changes, and renal sodium retention in liver cirrhosis. Gastroenterology (1993) 0.86
The effects of acute and chronic ingestion of ethanol on the autonomic nervous system. Drug Alcohol Depend (1986) 0.85
Carbon monoxide produced by intrasinusoidally located haem-oxygenase-1 regulates the vascular tone in cirrhotic rat liver. Liver Int (2008) 0.84
Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med (2005) 0.84
Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology (1995) 0.83
Differential response of the systemic and pulmonary circulation related to disease severity of cirrhosis. Transplant Proc (2005) 0.80
Autonomic dysfunction in chronic liver disease. Liver Int (2009) 0.80
The liver transplant recipient with cardiac disease. Transplant Proc (2008) 0.78
Alcohol abuse exaggerates autonomic dysfunction in chronic liver disease. Scand J Gastroenterol (1996) 0.78
Clinical predictors and characteristics of patients with chronic liver disease and intrapulmonary shunts. Clin Cardiol (2005) 0.77
Pulmonary hemodynamics and gas exchange after liver transplantation in patients with cirrhosis. Dig Dis Sci (2002) 0.77
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology (2007) 2.70
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl (2014) 2.25
Urgent vs. non-urgent endoscopy in stable acute variceal bleeding. Am J Gastroenterol (2009) 2.17
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int (2010) 1.77
Assessment of endoscopic training of general surgery residents in a North American health region. Gastrointest Endosc (2008) 1.71
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol (2004) 1.43
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care (2003) 1.29
Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21
Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19
Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol (2010) 1.18
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02
Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol (2010) 1.02
Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol (2005) 1.02
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95
Managing the post-liver transplantation anastomotic biliary stricture: multiple plastic versus metal stents: a systematic review. Gastrointest Endosc (2013) 0.95
Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93
Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2. Virology (2005) 0.93
Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev (2011) 0.93
Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92
Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int (2013) 0.92
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep (2013) 0.89
Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl (2010) 0.88
Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int (2007) 0.88
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience. Can J Gastroenterol (2010) 0.87
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? J Med Microbiol (2008) 0.86
Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology. Dig Dis Sci (2013) 0.86
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int (2008) 0.85
Cheating in scientific publishing: the scourge must stop! Liver Int (2008) 0.85
Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology (2003) 0.85
Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol (2004) 0.84
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis (2013) 0.84
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol (2013) 0.83
Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis (2007) 0.83
Cholangiocarcinoma: has there been any progress? Can J Gastroenterol (2010) 0.82
Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol (2008) 0.82
Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol (2005) 0.82
Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol (2002) 0.81
What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology (2005) 0.81
Third-generation cephalosporin-resistant spontaneous bacterial peritonitis: a single-centre experience and summary of existing studies. Can J Gastroenterol Hepatol (2013) 0.81
Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol (2008) 0.80
Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int (2012) 0.80
Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol (2011) 0.79
Pay now or pay (more) later: tracking the costs of hepatitis C infection. Can J Gastroenterol (2010) 0.79
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci (2014) 0.79
The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Am J Gastroenterol (2013) 0.79
Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr Opin Crit Care (2011) 0.78
Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open (2013) 0.78
Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol (2010) 0.78
Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt--When and How? Dig Dis (2015) 0.78
VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis. Liver Int (2013) 0.78
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci (2011) 0.77
Hepatic nodular regenerative hyperplasia in a patient with advanced carcinoid tumor. Eur J Gastroenterol Hepatol (2009) 0.77
The spleen is a player in portal hypertension. Exp Physiol (2012) 0.77
Role of ICAM-1 in chronic hepatic allograft rejection in the rat. Am J Physiol Gastrointest Liver Physiol (2002) 0.77
Implications of Treating Hepatitis C Virus Infection Among Patients Awaiting Cadaveric Liver Transplant: A Single-Center Experience. Exp Clin Transplant (2015) 0.77
Vasopressin antagonists and dilutional hyponatremia. Can J Gastroenterol (2004) 0.76
Soft and hard endpoints in acute variceal bleeding. Hepatology (2015) 0.76
Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol (2005) 0.76